Davin Rautiola

Davin Rautiola is CEO of Single Dose Therapeutics, where he is advancing a novel pharmacological approach to stimulant withdrawal and stimulant use disorder. With no FDA-approved medications currently available for stimulant use disorder, his work seeks to address neurobiological changes and persistent withdrawal symptoms that can contribute to relapse and make sustained recovery difficult. The company is developing a therapeutic candidate intended to support recovery by targeting mechanisms involved in learning, motivation, and behavioral regulation. The program initially focuses on amphetamine-type stimulants, with the longer-term goal of developing an FDA-approved pharmacotherapy for stimulant use disorder.